SK Biopharmaceuticals shares plunged by 17.29 percent Wednesday to 122,000 won ($109.7) as SK Holdings sold shares.
SK Holdings announced a strategic $200 million investment in Roivant Sciences to develop technology to discover drugs to treat cancer and other incurable diseases, the companies said Monday.
SK Holdings has established a business unit dedicated to hydrogen-related investment and plans to start mass-producing liquefied hydrogen from 2023, the company said Tuesday.
SK Biopharmaceuticals rose 160 percent from its offer price on its first day of trade, hitting two stock exchange-imposed limits on the way up. By market capitalization, it is now Korea's 27th largest company, just ahead of
SK Pharmteco’s U.S. subsidiary will manufacture ingredients of essential medicines, including those for Covid-19, under a massive funding campaign from the U.S. government worth up to $812 million.
SK Biopharmaceuticals launched its treatment for partial-onset seizures in adults with epilepsy in the U.S. market months after the company earned approval from the U.S. Food and Drug Administration (FDA) late last year.
SK Holdings has invested in a Singapore-based biopharmaceutical company, Hummingbird Bioscience, as the lead investor in a Series B funding round worth $25 million, SK said Monday.